Forecast

The analysts' average price target is €66.10 (+7.88%). The median is €73.16 (+19.41%).

Buy	16
Hold	8
Sell	1

News Go to news feed

Cooper Companies announces quarterly results for period ending 31 July 2026

Cooper Companies will likely publish results for the quarter ending 31 July 2026 on 9 September 2026. Fifteen analysts expect an average EPS of $1.12 per share versus $0.49 in the year-ago quarter. The revenue forecast averages $1.10 billion, an increase of 3.63% from $1.06 billion a year earlier. For the current fiscal year, analysts predict a median EPS of $4.63 and total revenue of $4.31 billion. » More on finanzen.net
Oakmark adds The Cooper Companies after pullback creates attractive entry point

Oakmark Global Fund initiated a position in The Cooper Companies, citing its strong contact-lens market position, recurring revenues, specialty-lens share gains and private-label strategy. The fund noted recent steps to improve free cash flow conversion, reaccelerate growth and optimize the product portfolio. Cooper's stock has pulled back with the med-tech sector and now trades at a meaningful discount to peers and its own history; it closed at $68.51 with a market cap of $13.36 billion. » More on finance.yahoo.com
Cooper Companies with record quarter and raised guidance drives institutional buying

Cooper Companies reported excellent quarterly results with sharply higher revenue and profit and strong margin improvement. The company raised its full-year 2026 guidance. Large investors then significantly increased their purchases, leading to a volume and price breakout of over 5%. Sustainable growth is expected mainly due to rising global demand for vision care products. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 1999, Cooper Companies has already paid €0.00244 in dividends. The last payout was in July 1999.

Financials

In the last quarter, Cooper Companies had revenue of €922.09M and net profit of -€66.42M

(EUR)	Apr 2026	YoY
Revenue	922.09M	4.18%
Gross profit	627M	4.55%
Net profit	-66.42M	185.76%
EBITDA	57.89M	74.91%

Fundamentals

Metric	Value
Market capitalization	€12.2B
Number of shares	195.03M
52-week high/low	€77.32 - €50.69
Dividends	No
Beta	0.82
P/E ratio	61.59
PEG ratio	-1.42
P/B ratio	1.72
P/S ratio	3.35

Company profile

The Cooper Companies, Inc. entwickelt, produziert und vertreibt zusammen mit ihren Tochtergesellschaften Kontaktlinsen. Das Unternehmen ist in zwei Segmenten tätig, CooperVision und CooperSurgical. Das Segment CooperVision bietet sphärische Linsen, einschließlich Linsen, die Kurz- und Weitsichtigkeit korrigieren, sowie torische und multifokale Linsen, die Linsen zur Korrektur von Sehproblemen wie Astigmatismus, Alterssichtigkeit, Kurzsichtigkeit, Augentrockenheit und Augenermüdung in Amerika, Europa, dem Nahen Osten, Afrika und dem asiatisch-pazifischen Raum umfassen. Das Segment CooperSurgical konzentriert sich auf die Familien- und Frauengesundheitspflege, die medizinische Geräte, Fruchtbarkeit, Genomik, Diagnostik und Empfängnisverhütung für medizinisches Fachpersonal und Patienten weltweit anbietet. Es bietet chirurgische und Büroprodukte, einschließlich PARAGARD, Uterusmanipulatoren, Retraktoren, Verschlussprodukte, Point-of-Care-Produkte, LEEP-Produkte, Endosee sowie Illuminate- und Fötus-Kissen; Fruchtbarkeitsprodukte und -dienstleistungen, wie Fruchtbarkeitsverbrauchsmaterial und -ausrüstung sowie Embryo-Optionen und Präimplantations-Gentests. The Cooper Companies, Inc. wurde 1958 gegründet und hat seinen Hauptsitz in San Ramon, Kalifornien.

Name	Cooper Companies
CEO	Albert G. White
Headquarters	San Ramon, ca USA
Website	coopercos.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	01/21/1983
Employees	15,000